Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5521MR)

This product GTTS-WQ5521MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5521MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ778MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ2533MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ11058MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ12442MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ6977MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ12984MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ11580MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ10513MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW